|
|
|
|
| LEADER |
00000cam a2200000M 4500 |
| 001 |
SCIDIR_on1396180593 |
| 003 |
OCoLC |
| 005 |
20231120010753.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
230907s2023 xx o 0|| 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d SFB
|d OPELS
|d OCLCO
|
| 020 |
|
|
|a 9780443221798
|q (electronic bk.)
|
| 020 |
|
|
|a 0443221790
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443221781
|
| 020 |
|
|
|z 0443221782
|
| 035 |
|
|
|a (OCoLC)1396180593
|
| 050 |
|
4 |
|a RC271.G45
|
| 082 |
0 |
4 |
|a 616.994042
|
| 245 |
0 |
0 |
|a Epigenetic regulation of cancer.
|n Part A /
|c edited by Sheila Spada, Lorenzo Galluzzi.
|
| 260 |
|
|
|a [S.l.] :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource.
|
| 490 |
0 |
|
|a International review of cell and molecular biology ;
|v v. 380
|
| 505 |
0 |
|
|a Front Cover -- Series page -- International Review of CELL AND MOLECULARBIOLOGY -- Copyright -- Contents -- Contributors -- Epigenetic regulation of cancer -- Acknowledgments -- Competing interests -- References -- Chapter One: Epigenetic regulation of epithelial-mesenchymal transition during cancer development -- 1 Introduction -- 2 Epigenetic modifications and human cancers -- 2.1 A brief overview of epigenetic modifications -- 2.1.1 Histone modifications -- 2.1.2 Modifications at DNA level -- 2.1.3 Modifications at mRNA and ncRNA levels -- 2.2 Roles of epigenetic modifications in cancer development -- 3 EMT and human cancers -- 3.1 A brief overview of EMT -- 3.1.1 EMT process -- 3.1.2 Transcription factors and signaling pathways involved in the EMT process -- 3.2 Roles of EMT in cancer development -- 4 Epigenetic regulation of EMT in human cancers -- 4.1 Regulation of EMT by histone modifications in human cancers -- 4.2 Regulation of EMT by DNA modifications in human cancers -- 4.3 Regulation of EMT by mRNA and ncRNA modifications in human cancers -- 5 Epigenetic therapy targeting EMT for management of human cancers -- 6 Conclusions and future perspectives -- Acknowledgements -- Declaration of competing interest -- References -- Chapter Two: Novel insights into DNA methylation-based epigenetic regulation of breast tumor angiogenesisNovel insights into DNA methylation-based epigenetic regulation of breast tumor angiogenesis -- 1 Introduction -- 1.1 DNA methylation-based regulation of breast tumor angiogenesis: What is known? -- 1.1.1 Identification of pro-angiogenic genes regulated by DNA methylation -- 1.1.2 Promoters of pro-angiogenic genes are hypomethylated and anti-angiogenic genes are hypermethylated in breast tumors -- 2 Conclusion -- 3 Future perspectives -- Acknowledgements -- Conflict of interest -- References.
|
| 505 |
8 |
|
|a Chapter Three: Super-enhancer landscape rewiring in cancer: The epigenetic control at distal sites -- 1 Introduction -- 2 Promoters and typical enhancers -- 3 Super-enhancers (SEs) -- 4 Super-enhancers identification -- 5 eRNAs -- 6 The Mediator complex -- 7 Chromatin remodelers -- 8 TADs, chromatin organization and distal CREs -- 9 Super-enhancer, phase separation and membraneless organells -- 10 SEs in cancer an introduction -- 11 SEs expansion or contraction in cancer -- 12 Subversion of hierarchically organization of SEs in cancer -- 12.1 SEs hierarchy in gastric adenocarcinoma -- 12.2 SEs hierarchy in breast cancer -- 12.3 SEs hierarchy in prostate cncer -- 12.4 SEs hierarchy in ovarian cancer -- 12.5 SEs hierarchy in colorectal cancer (CRC) -- 12.6 SEs hierarchy in hepatocellular carcinoma (HCC) -- 12.7 SEs hierarchy in sarcomas -- 12.8 SEs hierarchy in neuroblastoma and glioblastoma -- 12.9 SEs hierarchy in DLBCL -- 12.10 SEs hierarchy in leukemia -- 13 SEs and ncRNAs, dangerous liaisons in cancer progression -- 14 SEs and ncRNAs, altered circuits in resistance to therapy -- 15 SEs for classification of tumors subtypes or cancer ethnicity, predicts subclonal evolution and identify new druggable targets -- 15.1 Targeting specific SEs in cancer: going over to JQ-1 and THZ1 -- 16 Conclusions -- Acknowledgments -- Conflict of interest -- References -- Chapter Four: Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphomaNon-coding RNAs in CTCL -- 1 Introduction -- 2 miRNAs in CTCL -- 2.1 miRNA role in diagnosis, progression, and prognosis -- 2.1.1 Diagnosis -- 2.1.2 Progression -- 2.1.3 Prognosis -- 2.2 Oncogenic miRNAs in CTCL -- 2.2.1 miR-155 -- 2.2.2 miR-21 -- 2.3 Tumor-suppressive miRNAs in CTCL -- 2.3.1 miR-337 -- 2.3.2 miR-150 -- 3 Long non-coding RNAs in CTCL -- 3.1 Oncogenic lncRNA in CTCL -- 3.1.1 MALAT1.
|
| 505 |
8 |
|
|a 3.2 Tumor-suppressive lncRNAs in CTCL -- 3.2.1 MEG3 -- 4 Non-coding RNAs in CTCL patients -- 5 Conclusion and future perspectives -- Conflict of interest statement -- Funding -- References -- Chapter Five: Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer -- 1 Introduction -- 1.1 Chemotherapy: target, mode of action, limitation(s) -- 1.2 Androgen deprivation therapy -- 1.3 Androgen receptor blocker therapy -- 1.4 Immunotherapy -- 2 Epigenetic reprogramming-dependent aberrant regulation of genes during therapeutic resistance development in prostate cancers -- 3 Aberrant expression of epigenetic regulatory genes during therapeutic resistance in prostate cancer -- 4 Epigenetic regulation of DNA repair genes in prostate cancer chemoresistance -- 5 Epigenetic regulation of androgen-dependent growth in ADT in prostate cancer -- 6 Epigenetic regulation of genes associated with cellular plasticity during chemoresistance in prostate cancer -- 6.1 Epigenetic reprogramming of stem cell marker genes in chemotherapy resistance in prostate cancer -- 6.2 Epigenetic reprogramming of EMT marker genes in chemotherapy resistance in prostate cancer -- 7 Potential of epigenetics-based therapeutics in prostate cancer treatment -- 8 Summary -- References -- Chapter Six: Epigenetic inhibitors and their role in cancer therapy -- 1 Introduction -- 2 Epigenetic modifications -- 2.1 DNA methylation -- 2.2 Mechanisms of DNA methylation -- 2.3 Histone modifications -- 2.4 Histone methylation -- 2.5 Histone acetylation -- 2.6 Histone phosphorylation -- 2.7 Histone ubiquitination -- 2.8 RNA modifications -- 2.9 Non-coding RNA modifications -- 3 The role of epigenetics in cancer development -- 4 Epigenetics as a target for cancer therapies -- 5 Epi-drugs -- 5.1 DNA methyltransferase inhibitors.
|
| 505 |
8 |
|
|a 5.1.1 Nucleoside analog inhibitors -- 5.1.2 Non-nucleoside inhibitors -- 5.2 Histone methyltransferase inhibitors -- 5.3 Histone deacetylase inhibitors (HDACi) -- 6 Small non-coding RNAs -- 6.1 Small molecule inhibitors of miRNAs (SMIRs) -- 6.2 miRNA-based therapy -- 6.2.1 Epi-drugs combined therapy -- 6.3 Epi-drugs combined with chemotherapy -- 6.4 Epi-drugs combined with immunotherapy -- 7 Conclusion and future perspectives -- Acknowledgments -- CRediT authorship contribution statement -- Conflict of interest -- Funding -- References -- Backcover.
|
| 650 |
|
0 |
|a Cancer
|x Gene therapy.
|
| 650 |
|
0 |
|a Epigenetics.
|
| 650 |
|
6 |
|a Cancer
|x Th�erapie g�enique.
|0 (CaQQLa)201-0241421
|
| 650 |
|
6 |
|a �Epig�en�etique.
|0 (CaQQLa)000270630
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780443221798
|
| 776 |
0 |
8 |
|c Original
|z 0443221782
|z 9780443221781
|w (OCoLC)1390680295
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/19376448/380
|z Texto completo
|
